Prebiopsy MRI Oncologically Safe for Suspected Prostate Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 30, 2024 -- Men with negative multiparametric magnetic resonance imaging (mpMRI) results avoiding biopsy do not have an increased risk for clinically significant prostate cancer (PCa), according to a study published online Dec. 12 in JAMA Oncology.
Charlie A. Hamm, M.D., Ph.D., from Charité-Universitätsmedizin Berlin, and colleagues examined the feasibility and safety of a community-based MRI diagnostic strategy in men aged 18 to 75 years with suspected PCa. Participants underwent 3-Tesla mpMRI; those with findings suspected to be PCa were recommended for targeted prostate biopsy (PB). Men with negative mpMRI results or positive mpMRI results and benign findings on PB were monitored systematically for three years.
Overall, 593 men underwent mpMRI and 48 percent had negative MRI results; 44 and 41 percent avoided PB initially and over three years, respectively. The researchers found that clinically significant PCa was detected in 27 and 29 percent of men after immediate PB and after three years, respectively. Seven men with negative MRI results had PCa diagnosed by immediate PB and 279 entered the monitoring phase. A total of 233 completed three-year monitoring, with seven PCa diagnoses. Nineteen percent of the 307 men with positive MRI results showed no PCa after immediate PB; of these, 71 and 7 percent completed monitoring and were diagnosed with clinically significant PCa, respectively.
"By providing programmatic three-year monitoring data for both patients with negative and positive MRI results, findings from this study address the gap of knowledge highlighted in current guidelines on the use of MRI in the diagnosis and management of PCa," the authors write.
Several authors disclosed ties to pharmaceutical and medical technology companies, including Bayer Pharma AG and Siemens Healthineers, both of which contributed funding for the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer
FRIDAY, April 18, 2025 -- A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced...
CT Exams in 2023 Projected to Result in 103,000 Future Cancers
THURSDAY, April 17, 2025 -- At current utilization and radiation dose levels, computed tomography (CT) examinations in 2023 were projected to result in about 103,000 future...
Prostate Cancer Screening Program Beneficial in Top Decile of Polygenic Risk Score
MONDAY, April 14, 2025 -- A prostate cancer screening program involving participants in the top decile of risk according to a polygenic risk score identifies clinically...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.